High Cost of Medicine: A Common Concern for Americans

Among various issues plaguing the American healthcare system, the expense of medications stands out as a significant concern for many patients.

Surveys indicate that a majority of Americans find drugs to be prohibitively costly. They often hold this belief even when they consider that pricey medications can be more beneficial than surgery, hospital stays, or living with chronic pain.

President Donald Trump has promised to initiate healthcare reforms aimed at fostering innovation while also enhancing affordability.

Some people see these goals as opposing forces. However, it’s possible to achieve both objectives in the realm of pharmaceuticals simultaneously.

This week, we introduced a working group consisting of our preferred patients and a team of leading health and economic experts, all focused on reducing drug prices in a way that does not hinder the development of new medications.

Before suggesting any workable policies, we should be cautious about government-mandated price controls.

Top-down directives that eliminate profit incentives can stifle drug research and development, ultimately harming efforts to discover treatments for serious diseases like cancer, Alzheimer’s, and Parkinson’s.

This approach overlooks the fact that 93% of prescriptions in the U.S. are for affordable generics, which are often cheaper than their foreign counterparts. These generics typically emerge after innovators have secured a reasonable return on their investments.

Instead, let’s explore innovations that could have both medical and economic benefits.

First, we could enable patients to buy medications directly from pharmaceutical companies. A recent survey showed that 86% of voters in key states are in favor of this idea. This would reduce drug prices by sidestepping the high retail markups imposed by insurance companies and others.

Most voters also agree with Trump’s plans to address the high costs associated with intermediaries, particularly the pharmacy benefits industry, which negotiates drug prices for insurers.

Additionally, there’s a need to ensure that foreign countries contribute fairly to the costs of medical innovations developed in the U.S.

Trump could draw upon NATO negotiations as a model. Just as he urged European nations to increase their funding for NATO security, he could encourage trading partners to invest a larger share of their GDP in American drug development.

Currently, over 70% of global drug revenue originates from the U.S., even though this country accounts for less than a quarter of global GDP.

Americans spend about $13,000 per person annually on healthcare, while other developed nations leverage free market principles more effectively.

Trump has already initiated some of these reforms in his first trade deal, securing a commitment of approximately $300 billion for domestic drug R&D, manufacturing, and labor.

These commitments help share the responsibility for discovering treatments that benefit humanity, promoting the innovation that justifies investment.

The FDA urgently needs to modernize its slow drug approval process. When this process takes too long, many promising developments from small biomedical companies are left unrealized.

It’s essential for the FDA to expedite approvals for experimental drugs that can treat severe and fatal conditions, and to support the “right to try” rule that allows access to these promising medications.

Moreover, the FDA should consider relaxing its regulations and incorporate economic benchmarks alongside clinical standards to accelerate drug approvals.

Lastly, transparency in drug pricing and healthcare services can help lower costs and encourage patients to compare options more effectively.

We wouldn’t purchase food, gas, or homes without knowing the costs, so why should it be any different for medications and medical procedures?

Meanwhile, Republicans risk missing an opportunity to capitalize on this straightforward reform.

Voters often perceive the GOP as lacking compassion and reliability in addressing healthcare issues, a perception that has led to electoral defeats.

As the midterm elections approach, Republicans who advocate for innovation and adopt our recommendations could help reduce costs, secure America’s position in biomedical innovation, and ultimately save lives.

It’s a cause worth pursuing.